ATRC vs. TFX, ITGR, ATEC, IART, OFIX, ANGO, SRDX, ARAY, RMTI, and RSLS
Should you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Teleflex (TFX), Integer (ITGR), Alphatec (ATEC), Integra LifeSciences (IART), Orthofix Medical (OFIX), AngioDynamics (ANGO), Surmodics (SRDX), Accuray (ARAY), Rockwell Medical (RMTI), and ReShape Lifesciences (RSLS). These companies are all part of the "health care equipment" industry.
AtriCure vs.
AtriCure (NASDAQ:ATRC) and Teleflex (NYSE:TFX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, community ranking, valuation, profitability, dividends and risk.
AtriCure received 50 more outperform votes than Teleflex when rated by MarketBeat users. Likewise, 69.77% of users gave AtriCure an outperform vote while only 58.36% of users gave Teleflex an outperform vote.
AtriCure has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, Teleflex has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.
Teleflex has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.
Teleflex has a net margin of 7.85% compared to AtriCure's net margin of -9.61%. Teleflex's return on equity of 14.19% beat AtriCure's return on equity.
AtriCure presently has a consensus price target of $50.67, suggesting a potential upside of 52.34%. Teleflex has a consensus price target of $164.63, suggesting a potential upside of 34.98%. Given AtriCure's stronger consensus rating and higher probable upside, analysts clearly believe AtriCure is more favorable than Teleflex.
In the previous week, Teleflex had 18 more articles in the media than AtriCure. MarketBeat recorded 26 mentions for Teleflex and 8 mentions for AtriCure. AtriCure's average media sentiment score of 1.48 beat Teleflex's score of 0.53 indicating that AtriCure is being referred to more favorably in the media.
99.1% of AtriCure shares are owned by institutional investors. Comparatively, 95.6% of Teleflex shares are owned by institutional investors. 3.5% of AtriCure shares are owned by company insiders. Comparatively, 1.4% of Teleflex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
AtriCure beats Teleflex on 10 of the 18 factors compared between the two stocks.
Get AtriCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AtriCure Competitors List
Related Companies and Tools
This page (NASDAQ:ATRC) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy ATRC Stock Free ATRC Stock Alerts